Thus, we hypothesized that the LXR agonist might sensitize EGFR‐TKI‐resistant human lung cancer cells to EGFR‐TKI treatment by suppressing the EGFR‐PI3K‐AKT‐NF‐κB pathway. Here, AKT1 is linked to lung carcinoma.